Literature DB >> 15350177

Prevalence, pathophysiology and treatment of isolated systolic hypertension in the elderly.

Lutgarde Thijs1, Elly Den Hond, Tim Nawrot, Jan A Staessen.   

Abstract

Isolated systolic hypertension is the predominant type of hypertension in the elderly and is associated with cardiovascular complications such as stroke, coronary heart disease and heart failure. In this review, the role of arterial stiffness, endothelial function, atherosclerosis and oxidative stress in the pathogenesis of isolated systolic hypertension is extensively discussed. Placebo-controlled intervention trials such as the Systolic Hypertension in Europe Trial and the Systolic Hypertension in the Elderly Program have clearly shown that pharmacological treatment of isolated systolic hypertension improves outcome in the elderly. Nevertheless, isolated systolic hypertension remains the major subtype of untreated and uncontrolled hypertension.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15350177     DOI: 10.1586/14779072.2.5.761

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  6 in total

1.  The actions of azelnidipine, a dihydropyridine-derivative Ca antagonist, on voltage-dependent Ba2+ currents in guinea-pig vascular smooth muscle.

Authors:  H-L Zhu; T Tomoda; M Aishima; Y Ito; N Teramoto
Journal:  Br J Pharmacol       Date:  2006-10-03       Impact factor: 8.739

2.  Prevalence of isolated systolic hypertension (ISH) in Slovene hypertensive patients: insights from the "Quality of Healthcare in Slovenia" project.

Authors:  Marjetka Pal; Polonca Ferk; Brane Leskošek; Ivan Krajnc; Marjan Pajntar
Journal:  Wien Klin Wochenschr       Date:  2015-03-19       Impact factor: 1.704

Review 3.  Role of ambulatory blood pressure monitoring in elderly hypertensive patients.

Authors:  Miguel Camafort; Wook-Jin Chung; Jin-Ho Shin
Journal:  Clin Hypertens       Date:  2022-07-01

Review 4.  Targeting nitric oxide with drug therapy.

Authors:  R Preston Mason; John R Cockcroft
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-12       Impact factor: 3.738

5.  A large scale study of angiotensin II inhibition therapy in an elderly population: the CHANCE study.

Authors:  Roland Asmar; Sophie Nisse-Durgeat
Journal:  Vasc Health Risk Manag       Date:  2006

Review 6.  The evolution of systolic blood pressure as a strong predictor of cardiovascular risk and the effectiveness of fixed-dose ARB/CCB combinations in lowering levels of this preferential target.

Authors:  Jean-Jacques Mourad
Journal:  Vasc Health Risk Manag       Date:  2008
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.